Progress and impact of 20 years of a lymphatic filariasis elimination programme in South-East Asia

Abstract

Background The South-East Asia regional programme to eliminate lymphatic filariasis (LF) was launched in 2000. This study presents the progress and impact of the programme in the region. Methods Mass drug administration (MDA) and morbidity management data were accessed from the WHO preventive chemotherapy databank. The status of the programme in the nine South-East Asia countries was reviewed and progress was assessed. The impact of the programme on LF disease burden was estimated on the basis of the effectiveness of the MDA drugs against microfilaraemia and chronic disease. Results Under the MDA programme, 8.1 billion treatments were delivered in nine countries and 5.7 billion treatments were consumed by the target population during 2001–2018. Three of nine countries eliminated LF. Bangladesh is poised to reach its elimination goal by 2021. In the other five countries, 38–76% of intervention units completed intervention and surveillance is in progress. The MDA programme prevented or cured 74.9 million infections, equivalent to an 84.2% reduction. Close to 1 million lymphoedema patients and 0.5 million hydrocele patients were reported and are being provided with the minimum package of care. Conclusions The South-East Asia region's LF elimination programme reduced the burden of LF appreciably and is moving towards achieving the elimination goal in the next 8–10 y.

Factors influencing implementation of mass drug administration for lymphatic filariasis elimination: a mixed-method study in Odisha, India

“…Lymphatic filariasis is widely prevalent in the Southeast Asian region, with India being an endemic country ( Kapa and Mohamed, 2020 ). India contributes 42% of the global LF endemic population, despite the National Filariasis Control Program and its subsequent updated forms since 1955 ( Agrawal and Sashindran, 2006 ; Sawers and Stillwaggon, 2020 ).…”

Ethical challenges in mass drug administration for reducing childhood mortality: a qualitative study

“…MDA has been used to treat trachoma (a bacterial cause of blindness affecting nearly 2 million people annually) [ 3 , 4 ], and MDA programs are often used to control other neglected tropical diseases [ 5 – 8 ]. MDA programs have been applied in efforts to reduce the incidence of lymphatic filariasis, onchocerciasis, schistosomiasis, and soil-transmitted helminth infection [ 9 – 12 ] (though a recent meta-analysis found little evidence of deworming’s positive effects on height, anemia, cognition, school performance, or mortality[ 13 ]).…”